Medindia LOGIN REGISTER
Medindia

Drug Safety Labeling Changes - May 2012

Food and Drug Administration (FDA) announces important safety label changes for prescription drugs almost every month. By implementing the label changes the FDA warns a physician of new side- effects, adverse reactions, contra-indications and precautions necessary for a drug. This information is important for safe practice of medicine.

Key to Label Sections

  • C - Contraindications
  • W - Warnings
  • P - Precautions
  • AR - Adverse Reactions
Drug Name Sections Modified
C W P AR
Abobotulinumtoxin A Injection
Adalimumab
Albuterol and Ipratropium
Alefacept
Benazepril
Bevacizumab
Chlorhexidine
Chlorhexidine
Chlorhexidine
Clarithromycin
Clonidine
Daptomycin
Denosumab
Dexlansoprazole
Dexmethylphenidate hcl
Estradiol
Ethosuximide
Filgrastim
Fingolimod
Insulin Detemir
Iopromide
Iopromide
Lansoprazole
Lenalidomide
Linagliptin
Lisinopril
Lisinopril and Hydrochlorothiazide
Omeprazole and Sodium Bicarbonate
Pamidronate
Pantoprazole
Pioglitazone and Metformin
Pralatrexate Solution
Rabeprazole
Ulipristal Acetate
Ustekinumab
Venlafaxine

2016 - Monthly Summary Report for Drug Label Changes

2015 - Monthly Summary Report for Drug Label Changes

2014 - Monthly Summary Report for Drug Label Changes

2013 - Monthly Summary Report for Drug Label Changes

2012 - Monthly Summary Report for Drug Label Changes